Restoring sensitivity to targeted therapies

In this new episode of the mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Simon Powell, CEO of Ribonexus, a new company put together to develop and ultimately commercialise long-standing research programmes from Gustav Roussy, Institut Curie, the University of Strasbourg, and Pierre Fabre, to develop drugs that overcome tumour resistance to existing drug treatments.